These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20879969)

  • 1. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.
    Ghatak SB; Patel DS; Shanker N; Srivstava A; Deshpande SS; Panchal SJ
    Curr Diabetes Rev; 2010 Nov; 6(6):410-21. PubMed ID: 20879969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
    Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
    Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
    Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Pratley RE
    Expert Opin Pharmacother; 2009 Feb; 10(3):503-12. PubMed ID: 19191685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
    Irons BK; Weis JM; Stapleton MR; Edwards KL
    Curr Diabetes Rev; 2012 May; 8(3):169-82. PubMed ID: 22429011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alogliptin for the treatment of type 2 diabetes.
    White JR
    Drugs Today (Barc); 2011 Feb; 47(2):99-107. PubMed ID: 21431099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alogliptin benzoate for the treatment of type 2 diabetes.
    Seino Y; Yabe D
    Expert Opin Pharmacother; 2014 Apr; 15(6):851-63. PubMed ID: 24646052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI; Cabrera A; Charron D
    Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
    Davidson JA
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S27-37. PubMed ID: 21106865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M; Drincic A; Andukuri R
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
    Forst T; Bramlage P
    Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.